Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1923-2026

Oxoid Agglutinating Sera, Salmonella 9-0 R30957301 Recall

Oxoid Agglutinating Sera, Salmonella 9-0 R30957301

FDA recall Class II

Ongoing

FDA lists this Class II recall for Oxoid Agglutinating Sera, Salmonella 9-0 R30957301. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1923-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Mar 25, 2026
FDA report date
Apr 29, 2026
Quantity in commerce
117 US; 950 OUS
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Oxoid Agglutinating Sera, Salmonella 9-0 R30957301

Affected model & UDI checker

Search the exact identifiers published for Z-1923-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
Not specifiedOxoid Agglutinating Sera, Salmonella 9-0 R30957301Check source notice05056080500270
FDA code information

UDI-DI 05056080500270 lots 6172600, 6172741, 6171393, 6150168, 6107767, 3766399, 3766400, 3780497, 3719592, 3709358, 6266130, 6253410, 6260215, 6222350, 6233859, 6233858

View the original FDA recall notice

Why was this product recalled?

Affected lots are not performing to IFU criteria showing cross reactions with 2-0 within 60 seconds. Cross-reactivity may result in the misidentification of a Salmonella 9-O serotype as a 2-O serotype.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Remel Europe Ltd. take?

Firm began notifying consignees on March 25, 2026 via letters titled "Urgent: Medical Device Recall." Laboratory professionals are advised to review results and destroy any remaining inventory of affected lots. Affected lots should not be used for any clinical laboratory testing. Customers should complete and return the included acknowledgement form for replacement/credit to be processed. Notice should be passed on to all who need to be aware. Firm is investigating the root cause and will implement corrective and preventive actions to prevent future recurrence.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology